Illuminating druggable targets via interrogation of direct gpcr-kinase interactions g protein-coupled receptors (gpcrs) and kinases represent two of the most highly druggable classes of membrane…
Ended Project Grant Awarded Last action
- Award ID
- R03TR003700
- Recipient
-
University Of Utah UEI LL8GLEVH6MG3
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $455,824
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date
- Funding
-
- $303,324.20 Federal
- $152,500.00 Non-federal
- Place of performance
- Utah, USA
Award details come from USAspending.gov.
About this award
This $455,824.20 Project Grant from the National Center for Advancing Translational Sciences will fund research to identify direct interactions between understudied G protein-coupled receptors (GPCRs) and protein kinase A (PKA) isoforms. The University of Utah will utilize the National Institutes of Health's existing Prestwick Chemical Library and NanoBRETT kinase assay platforms to develop a high-throughput screening assay for GPCR-PKA interactions. This assay will then be applied to systematically evaluate interactions between GPCRs and PKA isoforms in the National Center for Advancing Translational Sciences' portfolio, with a focus on those involved in cancer biology, nervous system function, and cilia-related processes. The research aims to establish whether direct GPCR-PKA interactions represent a general regulatory mechanism in receptor biology. Results will provide insights into understudied proteins' functions and lay the groundwork for future therapeutic development efforts targeting such interactions.
Description
Illuminating druggable targets via interrogation of direct gpcr-kinase interactions g protein-coupled receptors (gpcrs) and kinases represent two of the most highly druggable classes of membrane proteins, serving as targets for over one-third of FDA-approved drugs. Nevertheless, both of these protein superfamilies remain therapeutically underexploited, as many gpcrs and kinases still lack clinically useful ligands. A significant number of these understudied gpcrs and kinases may communicate with one another via noncanonical mechanisms not captured by existing functional assays. Our goal is to identify these noncanonical mechanisms, which will not only teach US how understudied gpcrs affect cell physiology, but also help US develop new assays to identify therapeutically beneficial ligands. We have discovered a new gpcr- kinase communication mechanism that does not conform to traditional signaling paradigms in the gpcr field. Instead, active gpcrs directly bind to and sequesters protein kinase a catalytic (PKA-c) subunits at the membrane, blocking phosphorylation of soluble PKA substrates to ultimately affect a plethora of cellular signaling processes. We hypothesize that a significant number of understudied gpcrs in the IDG portfolio control their respective intracellular signaling mechanisms via sequestration of PKA-c. This new idea likely applies not just to the heavily studied PKA-c isoform, but also to the understudied PKA-c and PKA-c isoforms that are designated as IDG targets and implicated in cancer and metabolic disorders. In this R03 grant we critically evaluate the above hypothesis, in the process developing concepts and generating reagents to interrogate understudied gpcrs and kinases more generally. Our strategy is to design a high-throughput assay for gpcr / PKA-c interactions, and then use this assay to systematically evaluate interactions between the gpcrs and/or PKA-c isoforms in IDG's portfolio. By identifying and characterizing gpcr / PKA-c interactions on a broad scale, our work will reveal the extent to which gpcr / PKA-c interactions represent a general theme in receptor biology. The proposed studies will provide a foundation for at least one future R01 grant focusing on the specific gpcr / PKA-c interactions we identify, particularly those involved in developmental and cancer biology, nervous system function, and the biology of motile and primary cilia. The proposed research capitalizes on existing IDG- generated resources, including the presto-tango system and nanobret kinase target engagement assays, both of which we can use following relatively minor modifications, along with the amis database. The availability of these key reagents, combined with our expertise in cultured cell functional assays, will allow US to complete the project within one year. Our work will establish a new paradigm to understand and therapeutically target understudied gpcrs and kinases. This will provide major insights into these proteins' biological functions and regulatory mechanisms and enable efforts to identify drugs that modulate these interactions. Given the ubiquity of gpcrs and PKA in biology, our studies are likely to be relevant to many aspects of human health and disease.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$838 | $0 | |
| Amendment | -$838 | $0 | |
| Amendment | $152,500 | $0 | |
| Original award | $152,500 | $152,500 |
Quick answers
Who received award R03TR003700?
R03TR003700 was awarded to University Of Utah by National Center for Advancing Translational Sciences (National Institutes of Health) on March 15, 2021.
How much is award R03TR003700 worth?
$455,824 has been obligated on R03TR003700: $303,324 in federal funding and $152,500 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award